PL3377500T3 - Związki oksadiazaspiro do leczenia nadużywania i uzależnienia od narkotyków/leków - Google Patents
Związki oksadiazaspiro do leczenia nadużywania i uzależnienia od narkotyków/lekówInfo
- Publication number
- PL3377500T3 PL3377500T3 PL16797458.3T PL16797458T PL3377500T3 PL 3377500 T3 PL3377500 T3 PL 3377500T3 PL 16797458 T PL16797458 T PL 16797458T PL 3377500 T3 PL3377500 T3 PL 3377500T3
- Authority
- PL
- Poland
- Prior art keywords
- drug
- dependence
- treatment
- abuse
- oxadiazaspiro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382566 | 2015-11-16 | ||
| PCT/EP2016/001907 WO2017084752A1 (en) | 2015-11-16 | 2016-11-15 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3377500T3 true PL3377500T3 (pl) | 2023-01-23 |
Family
ID=54707728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16797458.3T PL3377500T3 (pl) | 2015-11-16 | 2016-11-15 | Związki oksadiazaspiro do leczenia nadużywania i uzależnienia od narkotyków/leków |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US10927128B2 (pl) |
| EP (1) | EP3377500B1 (pl) |
| JP (1) | JP6884974B2 (pl) |
| KR (2) | KR20250069710A (pl) |
| CN (1) | CN108349999A (pl) |
| AR (1) | AR106697A1 (pl) |
| AU (1) | AU2016356488B2 (pl) |
| CO (1) | CO2018004665A2 (pl) |
| DK (1) | DK3377500T3 (pl) |
| ES (1) | ES2932000T3 (pl) |
| HR (1) | HRP20221343T1 (pl) |
| HU (1) | HUE060275T2 (pl) |
| IL (1) | IL259035B (pl) |
| LT (1) | LT3377500T (pl) |
| MA (1) | MA43250B1 (pl) |
| MX (1) | MX384637B (pl) |
| MY (1) | MY193423A (pl) |
| PH (1) | PH12018500814A1 (pl) |
| PL (1) | PL3377500T3 (pl) |
| PT (1) | PT3377500T (pl) |
| RS (1) | RS63734B1 (pl) |
| SG (1) | SG11201803153RA (pl) |
| SI (1) | SI3377500T1 (pl) |
| SM (1) | SMT202200460T1 (pl) |
| TN (1) | TN2018000122A1 (pl) |
| TW (1) | TWI756196B (pl) |
| UA (1) | UA123775C2 (pl) |
| WO (1) | WO2017084752A1 (pl) |
| ZA (1) | ZA201802845B (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TN2018000122A1 (en) | 2015-11-16 | 2019-10-04 | Esteve Labor Dr | Oxadiazaspiro compounds for the treatment of drug abuse and addiction |
| WO2020157026A1 (en) * | 2019-01-28 | 2020-08-06 | Esteve Pharmaceuticals, S.A. | Hydroxylated derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain |
| IL310950A (en) | 2021-09-20 | 2024-04-01 | Esteve Pharmaceuticals Sa | Oxadiazaspiro compounds for use in the treatment of motoneuron degeneration or in neuroprotection |
| WO2024105225A1 (en) | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4244961A (en) * | 1978-10-26 | 1981-01-13 | Syntex (U.S.A.) Inc. | 1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents |
| US4332804A (en) | 1981-03-23 | 1982-06-01 | Syntex (U.S.A.) Inc. | 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones |
| US4353900A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
| US4353901A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones |
| US6114541A (en) | 1997-03-10 | 2000-09-05 | Hoffmann-La Roche Inc. | Method for the preparation of α-Bromo-Lactam derivatives |
| EP1716156A2 (en) * | 2004-02-10 | 2006-11-02 | F.Hoffmann-La Roche Ag | Chemokine ccr5 receptor modulators |
| RU2477136C2 (ru) | 2004-03-03 | 2013-03-10 | Вайтал Хэлф Сайнсис Пти Лтд | Алкалоидные составы |
| EP1634873A1 (en) | 2004-08-27 | 2006-03-15 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
| US7951816B2 (en) * | 2004-08-27 | 2011-05-31 | Ono Pharmaceutical Co., Ltd. | Compound containing basic group and use thereof |
| CN101228127B (zh) * | 2005-05-30 | 2012-05-16 | Msdk.K.公司 | 哌啶衍生物 |
| CN101203567A (zh) * | 2005-06-07 | 2008-06-18 | 西巴特殊化学品控股有限公司 | 抗刮擦聚烯烃 |
| DE102005030051A1 (de) | 2005-06-27 | 2006-12-28 | Grünenthal GmbH | Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| WO2007045462A2 (de) | 2005-10-19 | 2007-04-26 | Grünenthal GmbH | Neue vanilloid-rezeptor liganden und ihre verwendung zur herstellung von arzneimitteln |
| PT1961744E (pt) | 2005-11-18 | 2013-05-15 | Ono Pharmaceutical Co | Composto que contém um grupo básico e sua utilização |
| EP1829869A1 (en) | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands |
| EP1847542A1 (en) | 2006-04-21 | 2007-10-24 | Laboratorios del Dr. Esteve S.A. | Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor |
| CN101622241B (zh) | 2007-03-01 | 2013-05-22 | 田边三菱制药株式会社 | 苯并咪唑化合物及其医药用途 |
| EP1982714A1 (en) | 2007-04-16 | 2008-10-22 | Laboratorios del Dr. Esteve S.A. | Pyrano-pyrazole-amines |
| EP2020414A1 (en) * | 2007-06-20 | 2009-02-04 | Laboratorios del Dr. Esteve S.A. | spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
| EP2197876A1 (en) | 2007-08-29 | 2010-06-23 | Glaxosmithkline LLC | Thiazole and oxazole kinase inhibitors |
| EP2070933A1 (en) | 2007-12-07 | 2009-06-17 | Laboratorios del Dr. Esteve S.A. | Tricyclic triazolic compounds |
| CN102083839B (zh) | 2008-02-06 | 2014-03-26 | 阿斯利康(瑞典)有限公司 | 化合物 |
| EP2108643A1 (en) * | 2008-04-10 | 2009-10-14 | Laboratorios Del. Dr. Esteve, S.A. | 4-methyl-4, 5-dihydro-1H-pyrazole-3-carboxamide useful as a cannabinoid CB1 neutral antagonist |
| GB201016912D0 (en) * | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
| US8828996B2 (en) | 2011-03-14 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| GB201107985D0 (en) | 2011-05-13 | 2011-06-29 | Astrazeneca Ab | Process |
| WO2013052716A1 (en) * | 2011-10-07 | 2013-04-11 | Glaxosmithkline Llc | Fatty acid synthase inhibitors |
| JPWO2013115294A1 (ja) * | 2012-01-31 | 2015-05-11 | 東レ株式会社 | ジアザスピロウレア誘導体及びその医薬用途 |
| US9751881B2 (en) | 2013-07-31 | 2017-09-05 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| TW201615643A (zh) * | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物 |
| TW201615642A (zh) | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | 具有多重模式抗疼痛活性的１－氧雜－４，９－二氮雜螺十一烷化合物之醯胺衍生物 |
| TWI685497B (zh) * | 2014-06-02 | 2020-02-21 | 西班牙商伊史帝夫製藥公司 | 具有多重模式抗疼痛活性的１-氧雜-４,９-二氮雜螺十一烷化合物之烷基衍生物 |
| WO2016122994A1 (en) | 2015-01-29 | 2016-08-04 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| TN2018000122A1 (en) | 2015-11-16 | 2019-10-04 | Esteve Labor Dr | Oxadiazaspiro compounds for the treatment of drug abuse and addiction |
-
2016
- 2016-11-15 TN TNP/2018/000122A patent/TN2018000122A1/en unknown
- 2016-11-15 ES ES16797458T patent/ES2932000T3/es active Active
- 2016-11-15 KR KR1020257015708A patent/KR20250069710A/ko active Pending
- 2016-11-15 AR ARP160103486A patent/AR106697A1/es active IP Right Grant
- 2016-11-15 RS RS20221052A patent/RS63734B1/sr unknown
- 2016-11-15 DK DK16797458.3T patent/DK3377500T3/da active
- 2016-11-15 TW TW105137236A patent/TWI756196B/zh active
- 2016-11-15 PT PT167974583T patent/PT3377500T/pt unknown
- 2016-11-15 MY MYPI2018701503A patent/MY193423A/en unknown
- 2016-11-15 UA UAA201806353A patent/UA123775C2/uk unknown
- 2016-11-15 LT LTEPPCT/EP2016/001907T patent/LT3377500T/lt unknown
- 2016-11-15 MA MA43250A patent/MA43250B1/fr unknown
- 2016-11-15 SI SI201631621T patent/SI3377500T1/sl unknown
- 2016-11-15 US US15/774,407 patent/US10927128B2/en active Active
- 2016-11-15 CN CN201680066748.9A patent/CN108349999A/zh active Pending
- 2016-11-15 JP JP2018524257A patent/JP6884974B2/ja active Active
- 2016-11-15 WO PCT/EP2016/001907 patent/WO2017084752A1/en not_active Ceased
- 2016-11-15 PL PL16797458.3T patent/PL3377500T3/pl unknown
- 2016-11-15 SG SG11201803153RA patent/SG11201803153RA/en unknown
- 2016-11-15 HU HUE16797458A patent/HUE060275T2/hu unknown
- 2016-11-15 AU AU2016356488A patent/AU2016356488B2/en active Active
- 2016-11-15 KR KR1020187017092A patent/KR20180080327A/ko not_active Ceased
- 2016-11-15 SM SM20220460T patent/SMT202200460T1/it unknown
- 2016-11-15 HR HRP20221343TT patent/HRP20221343T1/hr unknown
- 2016-11-15 EP EP16797458.3A patent/EP3377500B1/en active Active
- 2016-11-15 MX MX2018005439A patent/MX384637B/es unknown
-
2018
- 2018-04-16 PH PH12018500814A patent/PH12018500814A1/en unknown
- 2018-04-30 IL IL259035A patent/IL259035B/en active IP Right Grant
- 2018-04-30 ZA ZA2018/02845A patent/ZA201802845B/en unknown
- 2018-04-30 CO CONC2018/0004665A patent/CO2018004665A2/es unknown
-
2020
- 2020-12-21 US US17/128,738 patent/US11649248B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272820B (en) | The history of sulfamoylpyrrolamide and their use as drugs to treat jaundice b | |
| IL258931A (en) | Therapeutic compounds and methods | |
| IL259441A (en) | Materials and methods for treatment of titin-based myopathies and other titinopaties | |
| EP3302442C0 (en) | DOSAGE FORMS AND THEIR USE | |
| IL256166B (en) | Compounds for use in treating neuromuscular disorders | |
| EP4212536C0 (en) | BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | |
| PL3265053T3 (pl) | Sposoby leczenia skóry | |
| LT3206715T (lt) | Kanabidiolio naudojimas tuberozinės sklerozės komplekso gydymui | |
| IL254552A0 (en) | Polycyclic carbamoylpyridone compounds and their pharmaceutical uses | |
| HUE061761T2 (hu) | Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében | |
| HUE049413T2 (hu) | Nazális porkészítmény hipoglikémia kezelésére | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| HUE055263T2 (hu) | 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére | |
| DK3328864T3 (da) | Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser | |
| LT3297653T (lt) | Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais | |
| IL256103B (en) | Compositions and methods for treating celiac sprue disease | |
| GB201617064D0 (en) | Compounds and their therapeutic use | |
| IL251404B (en) | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | |
| DK3302478T3 (da) | Pac-1 kombinations behandling | |
| ZA201802134B (en) | Therapeutic compounds and methods of use thereof | |
| PL3373922T3 (pl) | Kompozycje i sposoby do stosowania do leczenia homocystynurii | |
| ZA201802845B (en) | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | |
| HUE063820T2 (hu) | Módszerek kardiovaszkuláris betegségek kezelésére | |
| IL251392B (en) | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes | |
| DK3395350T3 (da) | Lægemiddel til behandling af hjerneinfarkt |